UCB Clinical trials

UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress

Published August 29, 2025 at 05:15 AM

(NYSE:UCB) 26 scientific abstracts, including two oral presentations, demonstrate UCB's ongoing commitment to advancing research for people living with epilepsies Data include an open-label extension study describing the long-term safety of FINTEPLA®▼ (fenfluramine)[1] and global functioning in...